Teva’s ProAir Digihaler (Albuterol Sulfate 117 mcg) Inhalation Powder Receives FDA Approval for Asthma & COPD Patients Aged 4 Years or Older

 Teva’s ProAir Digihaler (Albuterol Sulfate 117 mcg) Inhalation Powder Receives FDA Approval for Asthma & COPD Patients Aged 4 Years or Older

Teva’s ProAir Digihaler (Albuterol Sulfate 117 mcg) Inhalation Powder Receives FDA Approval for Asthma & COPD Patients Aged 4 Years or Older

Shots:
  • The approval is based on filled sNDA by Teva to the US FDA assessing ProAir Digihaler in COPD and asthma patients treating bronchospasm
  • The electronic device with built in sensors detects, records and stores all events and information that can be transmitted to a mobile application connected to the device by Bluetooth, further helping patients to consult with their healthcare providers
  • ·    ProAir Digihaler is a combination of breath-activated and multi-dose dry powder inhaler with albuterol, indicated to treat or prevent of bronchospasm in patients, with its expected launch in 2019

Click here to read full press release/ article | Ref: Business Wire| Image: Philly

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post